Tisch MS News

Results Published from Trial of Siponimod in Secondary Progressive MS

The Lancet recently published an article demonstrating the efficacy of a new MS medication, Siponimod, in secondary progressive MS patients. Siponimod is very similar to a currently available medication, called fingolimod or gilenya, but may have a better safety profile. The results of the study...

April 12, 2018

More

2018 American Academy of Neurology Conference

Your Tisch MS Researchers will be attending this year's 2018 AAN conference in Los Angeles California on April 21st-27th. Stay tuned for planned poster board presentations out of the Tisch MSRCNY lab! For more information on this year's conference, you can visit their website .

April 3, 2018

More

Happy Easter!

To our staff, friends & supporters celebrating Good Friday and Easter this weekend, we wish you a happy and healthy holiday weekend!

March 30, 2018

More

Chag Sameach!

Tisch MSRCNY wishes everyone observing Passover, a holiday filled with peace, prosperity and good health. Chag Sameach!

March 30, 2018

More

Tisch MSRCNY WINTER STORM CLOSING 3/21/18

Due to the impending storm and weather conditions, the Tisch MS Research Center of New York will be closed on Wednesday, March 21, 2018. Please stay safe and warm!

March 20, 2018

More

A Statement from Tisch MSRCNY on Hematopoietic Stem Cell Transplantation (AHSCT) to Treat Relapsing Remitting MS

written by Dr. Armistead Williams A new report from an annual meeting of hematologists showed positive results for using hematopoietic stem cell transplantation (AHSCT) to treat relapsing-remitting MS. The results reflect what we already know about AHSCT: that it is highly effective in relapsing-...

March 19, 2018

More

RESEARCHERS SHOW STEM CELL THERAPY MAY REVERSE DISABILITY IN MULTIPLE SCLEROSIS

For Immediate Release RESEARCHERS SHOW STEM CELL THERAPY MAY REVERSE DISABILITY IN MULTIPLE SCLEROSIS New York, NY – February 6, 2018 – Researchers at Tisch MS Research Center of New York (Tisch MSRCNY) have shown a stem cell-based treatment may reverse disability in progressive multiple sclerosis...

February 6, 2018

More

JAMA Neurology Examines Rituxan

This study, recently published in the journal JAMA Neurology, examined the use of Rituximab as a first-line MS treatment in Sweden. Rituximab is already extensively used in Sweden but this study showed the improved efficacy and safety of using Rituximab as a first MS treatment as compared to other...

January 24, 2018

More

Martin Luther King Jr.

Tisch MSRCNY will be closed on Monday, January 15th, in observance of Martin Luther King Jr. Day. "Faith is taking the first step even when you don't see the whole staircase." -Martin Luther King Jr.

January 12, 2018

More

2018 Team Tisch Planning

Do you have any 2018 races or fundraising plans? Consider joining Team Tisch MS. Whether it is running, biking, swimming, being a proud supporter, or just wanting to promote an important cause, we need your support! Find out more!

January 8, 2018

More

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.